Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma

Kim A. Margolin; Frederick R. Aronson; Mario Sznol; Michael B. Atkins; Nicolae Ciobanu; Richard I. Fisher; Geoffrey R. Weiss; James H. Doroshow; Michael H. Bar; Michael J. Hawkins; James W. Mier; Elisabeth Paietta; Ellen P. Gaynor; David H. Boldt

doi:10.1097/00002371-199106000-00008

Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma

Kim A. Margolin, Frederick R. Aronson, Mario Sznol, Michael B. Atkins, Nicolae Ciobanu, Richard I. Fisher, Geoffrey R. Weiss, James H. Doroshow, Michael H. Bar, Michael J. Hawkins, James W. Mier, Elisabeth Paietta, Ellen P. Gaynor, David H. Boldt

Oncology

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Interleukin-2 (IL-2) plus lymphokine-activated killer (LAK) cell therapy has antineoplastic activity in renal cancer and malignant melanoma. In order to explore the activity of this therapy in Hodgkin’s disease and non- Hodgkin’s lymphoma, the Extramural IL-2/LAK Working Group (ILWG) treated 27 patients on two protocols using high-dose IL-2 and autologous LAK cells. Two of 12 patients with Hodgkin’s disease experienced partial responses lasting 6 and 12 weeks. No patient with non-Hodgkin’s lymphoma responded (p=NS). The toxicities of therapy were similar to those reported by the ILWG from trials of IL-2/LAK in solid tumors, consisting of transient hemodynamic, cardiopulmonary, renal and hepatic dysfunction, skin rash, fever, and flu-like symptoms. In view of the low response rate and the brief duration of these responses, we do not recommend the regimens reported here for further investigation in Hodgkin’s disease or non-Hodgkin’s lymphomas.

Original language	English (US)
Pages (from-to)	214-220
Number of pages	7
Journal	Journal of Immunotherapy
Volume	10
Issue number	3
DOIs	https://doi.org/10.1097/00002371-199106000-00008
State	Published - Jun 1991

Keywords

Hodgkin’s disease
Interleukin-2
Lymphokine-activated killer cells
Non-Hodgkin’s lymphoma

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Pharmacology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00002371-199106000-00008

Cite this

Margolin, K. A., Aronson, F. R., Sznol, M., Atkins, M. B., Ciobanu, N., Fisher, R. I., Weiss, G. R., Doroshow, J. H., Bar, M. H., Hawkins, M. J., Mier, J. W., Paietta, E., Gaynor, E. P., & Boldt, D. H. (1991). Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma. Journal of Immunotherapy, 10(3), 214-220. https://doi.org/10.1097/00002371-199106000-00008

Margolin, KA, Aronson, FR, Sznol, M, Atkins, MB, Ciobanu, N, Fisher, RI, Weiss, GR, Doroshow, JH, Bar, MH, Hawkins, MJ, Mier, JW, Paietta, E, Gaynor, EP & Boldt, DH 1991, 'Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma', Journal of Immunotherapy, vol. 10, no. 3, pp. 214-220. https://doi.org/10.1097/00002371-199106000-00008

@article{564330e9dc5c4815a5c666c48edfc3e0,

title = "Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin{\textquoteright}s disease and non-hodgkin{\textquoteright}s lymphoma",

abstract = "Interleukin-2 (IL-2) plus lymphokine-activated killer (LAK) cell therapy has antineoplastic activity in renal cancer and malignant melanoma. In order to explore the activity of this therapy in Hodgkin{\textquoteright}s disease and non- Hodgkin{\textquoteright}s lymphoma, the Extramural IL-2/LAK Working Group (ILWG) treated 27 patients on two protocols using high-dose IL-2 and autologous LAK cells. Two of 12 patients with Hodgkin{\textquoteright}s disease experienced partial responses lasting 6 and 12 weeks. No patient with non-Hodgkin{\textquoteright}s lymphoma responded (p=NS). The toxicities of therapy were similar to those reported by the ILWG from trials of IL-2/LAK in solid tumors, consisting of transient hemodynamic, cardiopulmonary, renal and hepatic dysfunction, skin rash, fever, and flu-like symptoms. In view of the low response rate and the brief duration of these responses, we do not recommend the regimens reported here for further investigation in Hodgkin{\textquoteright}s disease or non-Hodgkin{\textquoteright}s lymphomas.",

keywords = "Hodgkin{\textquoteright}s disease, Interleukin-2, Lymphokine-activated killer cells, Non-Hodgkin{\textquoteright}s lymphoma",

author = "Margolin, {Kim A.} and Aronson, {Frederick R.} and Mario Sznol and Atkins, {Michael B.} and Nicolae Ciobanu and Fisher, {Richard I.} and Weiss, {Geoffrey R.} and Doroshow, {James H.} and Bar, {Michael H.} and Hawkins, {Michael J.} and Mier, {James W.} and Elisabeth Paietta and Gaynor, {Ellen P.} and Boldt, {David H.}",

year = "1991",

month = jun,

doi = "10.1097/00002371-199106000-00008",

language = "English (US)",

volume = "10",

pages = "214--220",

journal = "Journal of Immunotherapy",

issn = "1524-9557",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma

AU - Margolin, Kim A.

AU - Aronson, Frederick R.

AU - Sznol, Mario

AU - Atkins, Michael B.

AU - Ciobanu, Nicolae

AU - Fisher, Richard I.

AU - Weiss, Geoffrey R.

AU - Doroshow, James H.

AU - Bar, Michael H.

AU - Hawkins, Michael J.

AU - Mier, James W.

AU - Paietta, Elisabeth

AU - Gaynor, Ellen P.

AU - Boldt, David H.

PY - 1991/6

Y1 - 1991/6

N2 - Interleukin-2 (IL-2) plus lymphokine-activated killer (LAK) cell therapy has antineoplastic activity in renal cancer and malignant melanoma. In order to explore the activity of this therapy in Hodgkin’s disease and non- Hodgkin’s lymphoma, the Extramural IL-2/LAK Working Group (ILWG) treated 27 patients on two protocols using high-dose IL-2 and autologous LAK cells. Two of 12 patients with Hodgkin’s disease experienced partial responses lasting 6 and 12 weeks. No patient with non-Hodgkin’s lymphoma responded (p=NS). The toxicities of therapy were similar to those reported by the ILWG from trials of IL-2/LAK in solid tumors, consisting of transient hemodynamic, cardiopulmonary, renal and hepatic dysfunction, skin rash, fever, and flu-like symptoms. In view of the low response rate and the brief duration of these responses, we do not recommend the regimens reported here for further investigation in Hodgkin’s disease or non-Hodgkin’s lymphomas.

AB - Interleukin-2 (IL-2) plus lymphokine-activated killer (LAK) cell therapy has antineoplastic activity in renal cancer and malignant melanoma. In order to explore the activity of this therapy in Hodgkin’s disease and non- Hodgkin’s lymphoma, the Extramural IL-2/LAK Working Group (ILWG) treated 27 patients on two protocols using high-dose IL-2 and autologous LAK cells. Two of 12 patients with Hodgkin’s disease experienced partial responses lasting 6 and 12 weeks. No patient with non-Hodgkin’s lymphoma responded (p=NS). The toxicities of therapy were similar to those reported by the ILWG from trials of IL-2/LAK in solid tumors, consisting of transient hemodynamic, cardiopulmonary, renal and hepatic dysfunction, skin rash, fever, and flu-like symptoms. In view of the low response rate and the brief duration of these responses, we do not recommend the regimens reported here for further investigation in Hodgkin’s disease or non-Hodgkin’s lymphomas.

KW - Hodgkin’s disease

KW - Interleukin-2

KW - Lymphokine-activated killer cells

KW - Non-Hodgkin’s lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0025729794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025729794&partnerID=8YFLogxK

U2 - 10.1097/00002371-199106000-00008

DO - 10.1097/00002371-199106000-00008

M3 - Article

C2 - 1868045

AN - SCOPUS:0025729794

SN - 1524-9557

VL - 10

SP - 214

EP - 220

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

IS - 3

ER -

Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this